<div id="readability-page-1">Massachusetts biotech companies are tightening their belts as economic uncertainty mounts, pulling in less funding, laying off workers and delaying acquisitions, per a new industry report. Why it matters: The state is one of the world's top producers of drugs treating rare diseases and other conditions, outpacing Chinese competitors. The mix of tariffs, federal funding cuts and other barriers may shrink the region's lead. Driving the news:...</div>

Ultragenyx制藥

<p>馬薩諸塞州的生物技術公司正面臨經濟挑戰，導致資金減少、裁員和收購推遲。該州在稀有疾病藥物生產方面處於領先地位，但由於關税、聯邦資金削減和其他障礙，面臨失去競爭優勢的風險。這一趨勢突顯了在日益增長的不確定性中，行業所面臨的困境</p>

馬薩諸塞州的生物技術行業在面臨逆風和特朗普削減政策的情況下出現萎縮